Which biocompatibility testing labs are ready for ISO 10993-1:2026?

# How to Evaluate a Lab's Readiness for the Upcoming ISO 10993-1 Revisions With significant revisions to the ISO 10993-1 standard for biocompatibility anticipated in the coming years, medical device manufacturers face a critical challenge: how to select a testing laboratory partner that is prepared for the future. Since no laboratory can be formally accredited to a standard that has not yet been published, a proactive and thorough due diligence process is essential for mitigating regulatory risk and preventing costly project delays. The key to this evaluation is shifting the focus from current certifications to indicators of future readiness. This involves assessing a laboratory's proactive engagement with the standards community, the adaptability of its Quality Management System (QMS), and its capacity for strategic partnership. A well-prepared lab will not simply react to the new standard upon its release; it will have been actively preparing for the transition, understanding the implications of draft changes, and developing a clear plan for implementation. This forward-looking approach is the most reliable sign that a lab will be a stable, knowledgeable partner through the transition period and beyond. ### Key Points * **No Lab is "Certified" to a Future Standard:** It is impossible for a lab to be accredited to a draft or future version of ISO 10993-1. Evaluation must focus on indicators of preparedness, not existing certificates for the new standard. * **Standards Committee Involvement is a Key Indicator:** A laboratory with technical experts participating in standards committees (e.g., ISO/TC 194) demonstrates a deep, forward-looking understanding of upcoming changes and their practical implications. * **QMS Adaptability is Non-Negotiable:** A mature QMS will have a defined, documented process for monitoring, analyzing, and implementing new and revised standards, including gap analysis, procedure updates, and staff training. * **Look for Strategic, Consultative Communication:** A prepared partner should be able to discuss the potential impact of anticipated changes on a manufacturer’s testing strategy, such as shifts in chemical characterization or biological risk analysis, even before the standard is finalized. * **Focus on the Transition Plan:** The most critical questions revolve around the lab's specific plan for validating new methods, training personnel, and updating documentation to ensure a seamless transition for their clients' projects. * **Due Diligence is the Sponsor's Responsibility:** Ultimately, the medical device manufacturer is responsible for selecting a qualified vendor. A structured evaluation process is the best way to build confidence and de-risk a submission. --- ## Understanding the Challenge: Assessing Readiness for a Future Standard Selecting a contract research organization (CRO) or testing laboratory for biocompatibility is a standard part of medical device development. Typically, manufacturers verify a lab's qualifications by reviewing its ISO/IEC 17025 accreditation, Good Laboratory Practice (GLP) compliance, and track record with regulatory bodies like the FDA. However, evaluating a lab for a *future* standard requires a different approach. The core challenge is that there is no official certification to audit against. This uncertainty can create significant regulatory risk. A device submission could be delayed or rejected if the supporting biocompatibility data was generated using an outdated interpretation of the standard or if the final report does not meet the new requirements. Therefore, manufacturers must move beyond a simple checklist and adopt a more investigative, risk-based approach to vendor qualification. The goal is to find a partner who is not just technically competent today, but who has the systems and foresight to remain competent tomorrow. This requires a deep dive into their internal processes, technical expertise, and engagement with the broader regulatory and standards community. ## A Framework for Evaluating Lab Preparedness A structured evaluation can help manufacturers consistently and effectively assess a lab’s readiness for the upcoming ISO 10993-1 revisions. This framework is built on three key pillars: Technical Engagement, QMS Adaptability, and Strategic Communication. ### Pillar 1: Technical Engagement and Expertise This pillar focuses on assessing the depth of a lab's knowledge and its active participation in the field. A lab that is deeply engaged is more likely to anticipate changes and provide expert guidance. **Key Questions to Ask:** * **Standards Committee Participation:** "Do any of your technical experts or toxicologists serve on standards development committees, such as ISO/TC 194 or its working groups?" Involvement indicates a proactive stance and firsthand knowledge of the discussions shaping the new standard. * **Industry Leadership:** "Does your lab publish white papers, host webinars, or present at industry conferences on the topic of biocompatibility and the upcoming ISO 10993 changes?" A lab that is actively educating the industry is a strong indicator of leadership and expertise. * **Expertise in Evolving Areas:** "Can you describe your team's expertise in areas of anticipated change, such as chemical characterization (ISO 10993-18), toxicological risk assessment (ISO 10993-17), and the Biological Evaluation Plan (BEP)?" Ask for the credentials and experience of the staff who will be performing these risk assessments. ### Pillar 2: Quality Management System (QMS) Adaptability A robust QMS is the engine that will drive a smooth transition. It should be a dynamic system designed to handle change efficiently and compliantly. **Key Questions to Ask:** * **Process for Adopting New Standards:** "Can you provide a high-level overview of your standard operating procedure (SOP) for monitoring and implementing revised industry standards like ISO 10993-1?" A mature lab will have a formal, documented process. * **Gap Analysis Protocol:** "What is your process for conducting a gap analysis between the current standard and the new version once it is released?" This analysis is the foundation for all subsequent implementation activities. * **Implementation Timeline and Plan:** "What is your typical timeline and plan for updating test methods, validating procedures, training staff, and updating report templates after a major standard revision is published?" While they cannot give exact dates, they should be able to describe a clear, logical sequence of events. * **Client Communication During Transition:** "How will you notify us about changes that affect our ongoing or planned studies? What is your process for managing studies that are in-progress when the new standard becomes effective?" ### Pillar 3: Strategic Communication and Partnership Beyond technical execution, a top-tier lab acts as a strategic partner. Their ability to communicate clearly and provide consultative advice is a significant value-add, especially during a period of change. **Key Questions to Ask:** * **Consultative Discussion:** "Based on the publicly available draft information, what are the most significant changes you anticipate from the new standard, and how might they impact the testing strategy for a device like ours (e.g., a long-term implant vs. a limited-contact surface device)?" * **Impact on Biological Evaluation Plans (BEPs):** "How is your team preparing to update your BEP templates and risk assessment strategies to align with the revised standard?" The BEP is a critical document, and its structure will likely be influenced by the new standard. * **Risk-Based Approaches:** "Can you discuss how the new standard might further emphasize a risk-based approach and how your services are structured to support that?" This demonstrates if they are thinking strategically about the overall evaluation, not just executing individual tests. ## Strategic Considerations and the Role of Q-Submission While selecting a prepared lab is critical, the ultimate responsibility for the device’s regulatory strategy rests with the manufacturer. The data generated by the lab is just one component of a comprehensive biological evaluation submitted to regulatory authorities like the FDA. In situations involving novel materials, complex devices, or uncertainty about how to apply the revised ISO 10993-1 standard, engaging the FDA directly can be a powerful de-risking tool. The **Q-Submission Program** allows sponsors to request feedback from the agency on their proposed testing strategy *before* initiating costly and lengthy studies. A sponsor could propose a Biological Evaluation Plan based on their understanding of the upcoming standard and ask for FDA's feedback. This dialogue can provide clarity and alignment, reducing the risk of the agency later questioning the testing approach during the review of a 510(k), De Novo, or PMA submission. A well-prepared testing lab can be a valuable partner in preparing the documentation for such a Q-Submission. ## Finding and Comparing Biocompatibility Testing Services Providers Choosing the right lab is a critical decision that extends beyond technical capabilities. It is about finding a partner who can navigate regulatory change effectively. **A Step-by-Step Approach to Provider Selection:** 1. **Develop a Shortlist:** Identify labs with foundational qualifications, including ISO/IEC 17025 accreditation for relevant ISO 10993 series tests and a history of supporting successful FDA submissions. 2. **Create a Readiness Questionnaire:** Use the questions outlined in the "Pillars" framework above to create a standardized questionnaire. This allows for an objective, side-by-side comparison of different labs' preparedness. 3. **Conduct Technical Interviews:** Schedule calls with the technical and quality assurance leaders at your shortlisted labs—not just the sales representatives. The goal is to gauge their depth of knowledge and the maturity of their internal processes. 4. **Request a Transition Case Study:** Ask for a (non-confidential) example of how they managed a previous major standard revision, such as a past update to ISO 10993-5 (cytotoxicity) or ISO 10993-10 (sensitization). This provides concrete evidence of their capabilities. 5. **Evaluate Strategic Fit:** Consider which lab best aligns with your company's risk tolerance, communication style, and the specific needs of your device portfolio. Finding a partner who is not only compliant today but is actively preparing for the compliance challenges of tomorrow is the ultimate goal. To find qualified vetted providers [click here](https://cruxi.ai/regulatory-directories/biocompatibility_testing) and request quotes for free. ## Key FDA References When preparing a submission for the U.S. market, it is essential to consult FDA's own documentation in addition to international standards. Sponsors should refer to the latest versions of these documents on the FDA website. * **FDA Guidance: Use of International Standard ISO 10993-1, 'Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process'** - This is the primary guidance document explaining FDA's expectations for biocompatibility. * **FDA's Q-Submission Program Guidance** - Provides the process for requesting feedback from FDA on regulatory and testing strategies prior to a formal marketing submission. * **21 CFR Part 807, Subpart E – Premarket Notification Procedures** - The general regulations governing 510(k) submissions, where biocompatibility data is a common requirement for demonstrating substantial equivalence. --- *This article is for general educational purposes only and is not legal, medical, or regulatory advice. For device-specific questions, sponsors should consult qualified experts and consider engaging FDA via the Q-Submission program.* --- *This answer was AI-assisted and reviewed for accuracy by Lo H. Khamis.*